Richwine, Lisa - NewsBios Dossier 03-01-05 (Archive)
March 2005 Beat: Food and Drug Administration, Health, Medicine, Pharmaceuticals
Excerpt: Lisa Richwine monitors the Food and Drug Administration for Reuters, with a particular focus on actions that the regulatory agency takes that impact the pharmaceutical industry. She has written extensively on the status of COX-2 pain relievers, including Merck and Co.'s Vioxx, which was withdrawn from the market and recently approved for a return to public availability.
This is an archival NewsBio for Lisa Richwine, who at the time covered the FDA for Reuters. Report dated 03-01-05. Only $49.95. Can be updated within 24 hours (additional fees apply).
Keywords: Profiles, Biographies, Bios, Dossiers, Journalists, Reporters, Editors, Writers, Authors, Anchors, Producers, Freelance.
Excerpt: Lisa Richwine monitors the Food and Drug Administration for Reuters, with a particular focus on actions that the regulatory agency takes that impact the pharmaceutical industry. She has written extensively on the status of COX-2 pain relievers, including Merck and Co.'s Vioxx, which was withdrawn from the market and recently approved for a return to public availability.
This is an archival NewsBio for Lisa Richwine, who at the time covered the FDA for Reuters. Report dated 03-01-05. Only $49.95. Can be updated within 24 hours (additional fees apply).
Keywords: Profiles, Biographies, Bios, Dossiers, Journalists, Reporters, Editors, Writers, Authors, Anchors, Producers, Freelance.
- Item #: 030105RiLi
